Entasis Therapeutics, a clinical-stage biotech developing therapies for multi-drug resistant bacteria, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Waltham, MA-based company was founded in 2015 and booked $5 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol ETTX. Entasis Therapeutics filed confidentially on December 8, 2017. Credit Suisse and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
